Strategic Diagnostics Announces Successful Expansion of

Proprietary Antibody Technology into the Japanese Life Science Industry through 
Partnership with Oriental Yeast Company 
NEWARK, Del.--(BUSINESS WIRE)--January 30, 2007
Strategic Diagnostics Inc. (Nasdaq:SDIX) - today announced that
its partnership with the Oriental Yeast Company is meeting
commercialization targets for its Genomic Antibodies(TM) service
offering within the Japanese Life Science industry. 
In September of 2006 Oriental Yeast Company (OYC) and Strategic
Diagnostics Inc. (SDI) expanded their relationship by designating OYC
as SDI's exclusive distributor of Genomic Antibodies(TM) in Japan. In
a Japanese trade release, OYC projected a run-rate of $1 million in
incremental sales during the first year of commercialization. OYC has
a strong direct sales force with long standing relationships in the
leading Japanese Biotechnology, Diagnostic, and Pharmaceutical
companies. OYC was already representing SDI's large-scale production
antibody business for various mission critical reagents. 
"We are pleased with the initial effort of OYC's Life Sciences
team and the growing momentum in building demand for custom polyclonal
and monoclonal antibodies using our Genomic Antibodies(TM) technology
platform," commented Matt Knight, President and CEO of Strategic
Diagnostics. "With about 12 weeks now under our belt, we feel
confident that OYC will continue to see adoption of the Genomic
Antibodies(TM) platform, consistent with their sales projections." 
Genomic Antibodies(TM) technology generates novel antibody
reagents faster, more cost effectively, and without the need for
purified protein or peptide. Customers only need to supply genetic
sequence of their protein of interest electronically to begin
generating a custom antibody project. By using a proprietary vector
system, native protein is expressed by the host animal, in a manner
that elicits an immune response to the encoded protein. This method
allows the production of an antibody generated against the protein's
native structure, as opposed to standard methods that use a
synthesized surrogate. The advantages of this system allow the
development of reagents against traditionally intractable targets such
as highly conserved and transmembrane proteins. The system is highly
scaleable, allowing the generation of custom libraries consisting of
hundreds of antibodies. 
Oriental Yeast Company is a leader in supplying recombinant
proteins and custom recombinant services to the Life Science industry.
Its own innovative technology, HiCEP, is a proprietary, custom service
for gene analysis, which unlike traditional microarrays, does not
require the customer to have prior information about the target genes.
HiCEP is able to identify both small variations in expression levels
within living cells, and new transcripts within a cell. These new
transcripts can then be studied further for their role in disease by
using the newly discovered sequence as antigen information within the
Genomic Antibodies(TM) platform to create novel antibody tools. 
Toshikuni Naito, President and CEO of OYC commented, "Our
technologies are complementary and allow OYC to provide the innovative
tools and services that allow our customers to more rapidly and cost
effectively advance their research and discovery initiatives. We look
forward to both HiCEP and Genomic Antibodies(TM) playing an important
role in protein therapeutics and biomarker discovery." 
About Strategic Diagnostics Inc. 
Strategic Diagnostics Inc. develops, manufactures and markets
biotechnology-based detection solutions to a diverse customer base,
across multiple industrial and human health markets. By applying its
core competency of creating custom antibodies to assay development,
the Company produces unique, sophisticated diagnostic testing and
reagent systems that are responsive to customer diagnostic and
information needs. Customers benefit with quantifiable "return on
investment" by reducing time, labor, and/or material costs. All this
is accomplished while increasing accuracy, reliability and
actionability of essential test results. The Company is focused on
sustaining this competitive advantage by leveraging its expertise in
immunology, proteomics, bio-luminescence and other bio-reactive
technologies to continue its successful customer-focused research and
development efforts. Recent innovations in high throughput production
of antibodies from genetic antigens will complement the Company's
established leadership in commercial and custom antibody production
for the Research, Human/Animal Diagnostics, and Pharmaceutical
industries, and position the Company for broader participation in the
pharmacogenomics market. 
This news release contains forward-looking statements reflecting
SDI's current expectations. When used in this press release, the words
"anticipate", "could", "enable", "estimate", "intend", "expect",
"believe", "potential", "will", "should", "project", "plan" and
similar expressions as they relate to SDI are intended to identify
said forward-looking statements. Investors are cautioned that all
forward-looking statements involve risks and uncertainties, which may
cause actual results to differ from those anticipated by SDI at this
time. Such risks and uncertainties include, without limitation,
changes in demand for products, delays in product development, delays
in market acceptance of new products, retention of customers and
employees, adequate supply of raw materials, inability to obtain or
delays in obtaining fourth party, including AOAC, or required
government approvals, the ability to meet increased market demand,
competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully
described in SDI's public filings with the U.S. Securities and
Exchange Commission. 
Company Contact:
Strategic Diagnostics Inc.
Matthew H. Knight, 302-456-6789
Investor Contact:
Hayden Communications
Brett Maas, 646-536-7331
Press spacebar to pause and continue. Press esc to stop.